314 related articles for article (PubMed ID: 33837064)
1. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.
Picco G; Cattaneo CM; van Vliet EJ; Crisafulli G; Rospo G; Consonni S; Vieira SF; Rodríguez IS; Cancelliere C; Banerjee R; Schipper LJ; Oddo D; Dijkstra KK; Cinatl J; Michaelis M; Yang F; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Arena S; Voest EE; Bardelli A; Garnett MJ;
Cancer Discov; 2021 Aug; 11(8):1923-1937. PubMed ID: 33837064
[TBL] [Abstract][Full Text] [Related]
2. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells.
Lieb S; Blaha-Ostermann S; Kamper E; Rippka J; Schwarz C; Ehrenhöfer-Wölfer K; Schlattl A; Wernitznig A; Lipp JJ; Nagasaka K; van der Lelij P; Bader G; Koi M; Goel A; Neumüller RA; Peters JM; Kraut N; Pearson MA; Petronczki M; Wöhrle S
Elife; 2019 Mar; 8():. PubMed ID: 30910006
[TBL] [Abstract][Full Text] [Related]
3. WRN Is a Promising Synthetic Lethal Target for Cancers with Microsatellite Instability (MSI).
Chan EM; Foster KJ; Bass AJ
Cancer Treat Res; 2023; 186():313-328. PubMed ID: 37978143
[TBL] [Abstract][Full Text] [Related]
4. Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer.
Hao S; Tong J; Jha A; Risnik D; Lizardo D; Lu X; Goel A; Opresko PL; Yu J; Zhang L
Proc Natl Acad Sci U S A; 2022 Dec; 119(51):e2211775119. PubMed ID: 36508676
[TBL] [Abstract][Full Text] [Related]
5. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Ferretti S; Hamon J; de Kanter R; Scheufler C; Andraos-Rey R; Barbe S; Bechter E; Blank J; Bordas V; Dammassa E; Decker A; Di Nanni N; Dourdoigne M; Gavioli E; Hattenberger M; Heuser A; Hemmerlin C; Hinrichs J; Kerr G; Laborde L; Jaco I; Núñez EJ; Martus HJ; Quadt C; Reschke M; Romanet V; Schaeffer F; Schoepfer J; Schrapp M; Strang R; Voshol H; Wartmann M; Welly S; Zécri F; Hofmann F; Möbitz H; Cortés-Cros M
Nature; 2024 May; 629(8011):443-449. PubMed ID: 38658754
[TBL] [Abstract][Full Text] [Related]
6. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Quiroga D; Lyerly HK; Morse MA
Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
[TBL] [Abstract][Full Text] [Related]
7. WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
Chan EM; Shibue T; McFarland JM; Gaeta B; Ghandi M; Dumont N; Gonzalez A; McPartlan JS; Li T; Zhang Y; Bin Liu J; Lazaro JB; Gu P; Piett CG; Apffel A; Ali SO; Deasy R; Keskula P; Ng RWS; Roberts EA; Reznichenko E; Leung L; Alimova M; Schenone M; Islam M; Maruvka YE; Liu Y; Roper J; Raghavan S; Giannakis M; Tseng YY; Nagel ZD; D'Andrea A; Root DE; Boehm JS; Getz G; Chang S; Golub TR; Tsherniak A; Vazquez F; Bass AJ
Nature; 2019 Apr; 568(7753):551-556. PubMed ID: 30971823
[TBL] [Abstract][Full Text] [Related]
8. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures.
Mengoli V; Ceppi I; Sanchez A; Cannavo E; Halder S; Scaglione S; Gaillard PH; McHugh PJ; Riesen N; Pettazzoni P; Cejka P
EMBO J; 2023 Feb; 42(3):e111998. PubMed ID: 36541070
[TBL] [Abstract][Full Text] [Related]
9. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
[TBL] [Abstract][Full Text] [Related]
10.
Zimmer K; Puccini A; Xiu J; Baca Y; Spizzo G; Lenz HJ; Battaglin F; Goldberg RM; Grothey A; Shields AF; Salem ME; Marshall JL; Korn WM; Wolf D; Kocher F; Seeber A
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455893
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy.
Wu H; Ma W; Jiang C; Li N; Xu X; Ding Y; Jiang H
Ann Surg Oncol; 2023 Dec; 30(13):8572-8587. PubMed ID: 37667098
[TBL] [Abstract][Full Text] [Related]
12. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
15. Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability.
Yang H; Kang M; Jang S; Baek SY; Kim J; Kim GU; Kim D; Ha J; Kim JS; Jung C; Kim NJ; Cho SY; Shin WH; Lee J; Ko J; Lee A; Keum G; Lee S; Kang T
Bioorg Med Chem; 2024 Feb; 100():117588. PubMed ID: 38295487
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
17. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
Roset M; Amonkar M; Patel R; Lara N; Kothari S
Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
